Keywords: HDV; Genotype 3; Treatment; PEG-IFN; Entecavir
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy
Keywords: Hepatitis C; Relapse; Direct-acting antivirals; Neutralizing antibodies; Sustained virological response; E1E2 envelope; HCV; hepatitis C virus; DAA; direct-acting antiviral; SVR; sustained virological response; RBV; ribavirin; PEG-IFN; pegylated-interfero
Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection
Keywords: CAM; ER Stress Response; Assembly Inhibitor Core Protein; Replication; DAA; ALT; alanine aminotransferase; CAM; capsid assembly modulator; cccDNA; covalently closed circular DNA; ER; endoplasmatic reticulum; ETV; entecavir; h-Alb; human albumin; HAP; hete
Deep sequencing identifies hepatitis B virus core protein signatures in chronic hepatitis B patients
Keywords: Hepatitis B virus core protein; Chronic hepatitis B; Deep sequencing; HBeAg status; Treatment response; HBV; hepatitis B virus; CHB; chronic hepatitis B; NUC; nucleos(t)ide analogues; peg-IFN; pegylated interferon; HBsAg; hepatitis B surface antigen; HBc;
Impact of hepatitis B vaccination on HBsAg kinetics, interferon-inducible protein 10 level and recurrence of viremia
Keywords: CccDNA; covalently closed circular DNA; CHB; chronic hepatitis B; ECLIA; Electrochemiluminescence immunoassay; ELISA; Enzyme-linked immunosorbent assay; HBsAg; HBV surface antigen; HCC; hepatocellular carcinoma; HOMA-IR; Homeostatic model assessment for i
Identification of KX2-391 as an inhibitor of HBV transcription by a recombinant HBV-based screening assay
Keywords: Recombinant HBV encoding NanoLuc; Anti-HBV compounds; Tubulin polymerization inhibitor; HBV transcription; HNF4A; HBV; Hepatitis B virus; PEG-IFN; pegylated interferon alpha; NTCP; sodium taurocholate cotransporting polypeptide; HNF4A; Hepatocyte nuclear
Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT)
Keywords: HCV; hepatitis C virus; CHC; chronic hepatitis C; HCC; hepatocellular carcinoma; LT; liver transplantation; PEG-IFN; pegylated interferon; RBV; ribavirin; SVR; sustained virological response; ANRS; France REcherche Nord & sud Sida-HIV Hépatites-FRENSH; V
International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement
Keywords: HCV; hepatitis C virus; HCV-EHMs; HCV-extrahepatic manifestations; IFN; interferon; CV; cryoglobulinemic vasculitis; AVT; antiviral therapy; Peg-IFN; pegylated interferon; RBV; ribavirin; DAAs; direct-acting antiviral agents; FDA; food and drug administra
Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C
Keywords: CHC; chronic hepatitis C; HCV; Hepatitis C virus; PEG-IFN; pegylated interferon alfa; RBV; ribavirin; DAAs; direct-acting antiviral agents; GT1; genotype 1; GT4; genotype 4; IQR; inter-quartile range; OR; odds ratio; HCV; IL28B; Liver stiffness; Fibrosis
What is new on HBsAg and other diagnostic markers in HBV infection?
Keywords: HBsAg; HBcrAg; HBV RNA; PEG-IFN; Nucleos(t)ide analogues; HBV infection;
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications
Keywords: ANRS CirVir; HCV Clearance; Direct Antivirals; Prognosis; AFP; α-fetoprotein; ANRS CO12 CirVir; Agence Nationale pour la Recherche sur le SIDA et les hépatites virales cohort 12 viral cirrhosis; BI; bacterial infection; CumI; cumulated incidence; DAA; d
Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection
Keywords: Chronic hepatitis B; Antiviral therapy; IFN signaling pathway; STAT1; MX; Peg-IFN; pegylated interferon; HBeAg; hepatitis B e antigen; HBsAg; hepatitis B surface antigen; NAs; nucleot(s)ide analogues; CHB; chronic hepatitis B; ETV; entecavir; ISGs; interf
Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon
Keywords: Hepatitis B treatment; PEG-IFN; HBV genotype; qHBsAg; HBeAg-negative; HBV; Hepatitis B virus; NA; nucleos(t)ide analogues; CHB; chronic hepatitis B; PEG-INF; pegylated interferon; HBsAg; hepatitis B surface antigen; ALT; alanine aminotransferase; HBeAg; h
Effect of interleukin-10 gene promoter polymorphisms -1082 G/A and -592 C/A on response to therapy in children and adolescents with chronic hepatitis C virus infection
Keywords: HCV; hepatitis C virus; Th1; Type 1 helper T cells; Th2; Type 2 helper T cells; IL; interleukin; SNPs; single nucleotide polymorphisms; PEG-IFN; pegylated interferon; AST; aspartate amino transferase; ALT; alanine amino transferase; GGT; gamma-glutamyl tr
ReviewIdeal oral combinations to eradicate HCV: The role of ribavirin
Keywords: HCV; hepatitis C virus; SVR; sustained virological response; RBV; ribavirin; IFN; interferon; Peg-IFN; pegylated interferon; DAA; direct-acting antiviral; ALT; alanine transaminase; GTP; guanosine triphosphate; IMPDH; inosine monophosphate dehydrogenase;
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension
Keywords: Esophagus; Bleeding; Long-Term Outcome; Portal Pressure; ALT; alanine-aminotransferase; DAA; direct-acting antivirals; EGS; esophageal gastroscopy; EV; esophageal varices; HCC; hepatocellular carcinoma; HCV; hepatitis C virus; LD; liver decompensation; LT
A Variant in PNPLA3 Associated With Fibrosis Progression but not Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection
Keywords: HALT-C cohort; Viral hepatitis; Cirrhosis; Hepatitis C; Liver cancer; adiponutrin; CI; confidence interval; HALT-C; Hepatitis C Antiviral Long-Term Treatment against Cirrhosis; HCC; hepatocellular carcinoma; HCV; hepatitis C virus; NASH; nonalcoholic stea
Roles of ITPA and IL28B genotypes in chronic Hepatitis C patients treated with peginterferon plus ribavirin in Tunisian population
Keywords: ITPA; inosine triphosphate; SVR; sustained virological response; HCV; hepatitis C virus; HCC; hepatocellular carcinoma; PEG-IFN; pegylated interferon; GWAS; Genome Wide Association Study; SNPs; single nucleotide polymorphisms; III IFN; interferon III; IL2
Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients
Keywords: HCV; Direct-acting antivirals; Resistance-associated variants (RAVs); NS3; NS5B; Peg-IFN;
Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy
Keywords: IL28B; HCV genotype 3; PEG-IFN
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme
Keywords: Hepatitis C; Telaprevir; HIV; Coinfection; Cirrhosis; Bridging fibrosis; DAA; direct acting antivirals; HAART; highly active anti-retroviral therapy; HCV; hepatitis C virus; HIV; human immunodeficiency virus; PEG-IFN; peginterferon;
Research ArticleQuantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study
Keywords: CHB; chronic hepatitis B; HBV; hepatitis B virus; HCC; hepatocellular carcinoma; cccDNA; covalently closed circular DNA; HBsAg; hepatitis B surface antigen; peg-IFN; pegylated interferon; HBeAg; hepatitis B e antigen; ETV; entecavir; TDF; tenofovir disopr
SKI-1/S1P inhibitor PF-429242 impairs the onset of HCV infection
Keywords: HCV; hepatitis C virus; HCVpp; HCV pseudotyped particles; HCVcc; cell culture produced HCV virions; VSVpp; vesicular stomatitis virus pseudotyped particles; HDV; hepatitis delta virus; SKI-1/S1P; subtilisin/hexin-isoenzyme-1/site-1 protease; SRE; sterol r
Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection
Keywords: Cell-to-Cell Spread; oxLDL; SVR; SR-BI; DAA; direct-acting antiviral drug; DMEM; Dulbecco's modified Eagle medium; DTT; dithiothreitol; HCV; hepatitis C virus; HCVcc; cell culture-grown hepatitis C virus; IPS1; interferon promoter stimulator-1; ITX-50
Case ReportOccasional spontaneous clearance of chronic hepatitis C virus in HIV-infected individuals
Keywords: HCV; hepatitis C virus; HIV; human immunodeficiency virus; IL28B; interleukin 28B; peg-IFN; pegylated interferon; HBV; hepatitis B virus; SNP; single nucleotide polymorphism; ART; antiretroviral treatment; ALT; alanine transaminase; AST; aspartate transam
Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms
Keywords: HCV; hepatitis C virus; HCV-4; hepatitis C virus genotype 4; PEG-IFN; pegylated interferon alfa; SVR; sustained virological response; RVR; rapid virological response; EVR; early virological response; SNP; single nucleotide polymorphism; IL; interleukin; N
Research ArticleVitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: A systematic review and meta-analysis
Keywords: HCV; hepatitis C virus; PEG-IFN; pegylated interferon; RBV; ribavirin; DAA; direct acting antiviral; 25(OH)D; 25-hydroxyvitamin D; SVR; sustained virologic response; RCT; randomized controlled trial; HIV; human immunodeficiency virus; Cholecalciferol; Vit
Hepatocyte expression of TRAIL pathway regulators correlates with histopathological and clinical parameters in chronic HCV infection
Keywords: cFLIP; cellular FLICE/caspase-8-inhibitory protein; cEVR; complete early viral response; CMV; cytomegalovirus; DR; death receptor; EBV; Epstein-Barr virus; EVR; early virologic response; FADD; FAS-associated via death domain; HCC; hepatocellular carcino
Post-treatment Levels of α-Fetoprotein Predict Incidence of Hepatocellular Carcinoma After Interferon Therapy
Keywords: ALT; Liver Cancer; Risk Factor; Response to Therapy; Outcome; AFP; α-fetoprotein; AFP24; α-fetoprotein levels at 24 weeks after the end of treatment; ALT; alanine aminotransferase; ALT24; alanine aminotransferase levels at 24 weeks after the end of trea
Hepatitis B and C in African Americans: Current Status and Continued Challenges
Keywords: Hepatitis B; Hepatitis C; African American; Black; Disparities; HBeAg; hepatitis B e antigen; HBsAg; hepatitis B surface antigen; HBV; hepatitis B virus; HCC; hepatocellular carcinoma; HCV; hepatitis C virus; IFN; interferon; IL; interleukin; MELD; Model
Epidemiology and impact of HIV coinfection with Hepatitis B and Hepatitis C viruses in Sub-Saharan Africa
Keywords: 3TC; Lamivudine; AOR; Adjusted Odds Ratio; ADV; adefovir; ALT; alanine transaminase; Anti-HBcAb; antibody to Hepatitis B core antigen; Anti-HBeAb; antibody to Hepatitis B e-antigen; Chronic hepatitis B; persistence of HBsAg >6months; d4T; Stavudine; ddI;
Management of Hepatitis B: Our Practice and How It Relates to the Guidelines
Keywords: Chronic Hepatitis B; Management; Antiviral Therapy; Hepatitis B Guidelines; AASLD; American Association for the Study of Liver Diseases; AFP; α-fetoprotein; ALT; alanine aminotransferase; anti-HBc; hepatitis B core antibody; anti-HBe; hepatitis B e antib
Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs
Keywords: CHB; chronic hepatitis B; peg-IFN; pegylated interferon-alpha; NA; nucleotide analogs; BL; baseline; W48; week 48; W96; week 96; W120; week 120; Add-on Peg-interferon; HBsAg; HBeAg;
Structural and functional characterization of the single-chain Fv fragment from a unique HCV E1E2-specific monoclonal antibody
Keywords: CDR; complementarity-determining region; DAAs; direct-acting antivirals; ELISA; enzyme-linked immunoabsorbent assay; FR; framework region; GT; genotype; HCV; hepatitis C virus; HCVsp; serum-derived HCV particles; HRP; horseradish peroxidase; IgG; immunogl
Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients
Keywords: EPO; erythropoietin; EPO-R; EPO receptor; HCV; hepatitis C virus; NK; natural killer; DC; dendritic cell; PEG-IFN; pegylated interferon-alpha; Hb; hemoglobin; PBMCs; peripheral blood mononuclear cells; ROS; reactive oxidative species; PHA; phytohemaggluti
Original ResearchFull Report: Basic and Translational-LiverA Serine Palmitoyltransferase Inhibitor Blocks Hepatitis C Virus Replication in Human Hepatocytes
Keywords: Direct-Acting Antiviral Agents; DAAs; HCV Lifecycle; Drug; cDNA; complementary DNA; DAA; direct-acting antiviral agent; HCV; hepatitis C virus; IC50; 50% inhibitory concentration; PCR; polymerase chain reaction; PEG-IFN; pegylated interferon alfa-2a; RBV;
Long-term Results of Treatment with Nucleoside and Nucleotide Analogues (Entecavir and Tenofovir) for Chronic Hepatitis B
Keywords: Personalized medicine; PEG-IFN; Analogues; Cirrhosis; Fibrosis regression;
Emerging Therapeutic Targets for Hepatitis C Virus Infection
Keywords: Hepatitis C; Direct Acting Antivirals; Interferon-free Therapy; Telaprevir; Boceprevir; DAA; direct acting antiviral; HCV; hepatitis C virus; IL; interleukin; NS; nonstructural; Peg-IFN; pegylated interferon; quad; quadruple; RBV; ribavirin; RGT; response
HBsAg Quantification to Predict Natural History and Treatment Outcome in Chronic Hepatitis BÂ Patients
Keywords: Personalized medicine; Prediction; PEG-IFN; Analogues; HBV tools; Prognosis;
Clinical Presentation, Outcome, and Response to Therapy Among Patients With Acute Exacerbation of Chronic Hepatitis C
Keywords: Hepatic Flare; Cirrhosis; Response to Therapy; Complication; ALT; alanine aminotransferase; AST; aspartate aminotransferase; CHC; chronic hepatitis C; HAI; Histologic Activity Index; HAV; hepatitis A virus; HBsAg; hepatitis B surface antigen; HCC; hepatoc
Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment
Keywords: HCV; hepatitis C virus; SVR; sustained viral response; Peg-IFN; pegylated interferon α; NS3; non-structural 3; HLA; human leukocyte antigen; AA; amino acid; Hepatitis C virus; Antiviral treatment; Direct acting antiviral (DAA); Protease inhibitor; Telapr
Will Interferon-Free Regimens Prevail?
Keywords: CHC; chronic hepatitis C virus infection; DAA; direct-acting antiviral; HTA; host-targeting agent; Peg-IFN; peginterferon; RAV; resistance-associated amino acid variant; RBV; ribavirin; RVR; rapid virologic response; SVR; sustained virologic response;
Research ArticleIL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C
Keywords: GWAS; genome wide association study; HCV; hepatitis C virus; IFN-λ3; interferon λ3; IL28B; interleukin 28B; NR; non response; PCR; polymerase chain reaction; PEG-IFN; pegylated interferon; RVR; rapid virological response; SNP; single nucleotide polymorp
Research ArticleValidation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a
Keywords: HBeAg; hepatitis B e antigen; CHB; chronic hepatitis B; NA; nucleos(t)ide analogues; HBV; hepatitis B virus; PEG-IFN; peginterferon; SR; sustained response; HBsAg; hepatitis B surface antigen; ALT; alanine aminotransferase; ULN; upper limit of normal; PCR
Research ArticleA multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse
Keywords: HCV; hepatitis C virus; SVR; sustained virological response; ALT; alanine amino transferase; Peg-IFN; pegylated interferon; ASI; addiction severity index; ISRs; interviewer severity ratings; OR; odds ratio; CI; confidence interval; IQ; interquartil; Case-
Research ArticlePrediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load
Keywords: HCV; hepatitis C virus; Peg-IFN; pegylated interferon; RBV; ribavirin; SNP; single nucleotide polymorphism; IL28B; interleukin 28B; SVR; sustained virologic response; DAA; directly acting agents; Hepatitis C; Interleukin 28B; Interferon; Ribavirin; Genoty
Research ArticleTelaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
Keywords: PEG-IFN; peginterferon; RBV; ribavirin; SVR; sustained virological response; SOC; standard of care; DAA; direct acting antiviral; Telaprevir; Chronic hepatitis C; Peginterferon; Ribavirin; Sustained virological response; Genotypes;
Research ArticleA randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C
Keywords: HCV; hepatitis C virus; ALT; alanine aminotransferase; AST; aspartate aminotransferase; PEG-IFN; pegylated interferon; RBV; ribavirin; SVR; sustained virological response; RVR; rapid virological response; cEVR; complete early virological response; ETR; en
Different mechanisms of hepatitis C virus RNA polymerase activation by cyclophilin A and B in vitro
Keywords: BSA; bovine serum albumin; CsA; cyclosporine A; CyP; cyclophilin; DTT; dithiothreitol; E; envelope; EDTA; ethylenediaminetetraacetic acid; GST; glutathione S-transferase; HCV; hepatitis C virus; NS; nonstructural protein; PPI; peptidyl prolyl cis/trans-is
Research ArticleA phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
Keywords: AUC; area under the plasma concentration-time curve; BMI; body mass index; EC50; 50% effective inhibitory concentration; EC90; 90% effective inhibitory concentration; HCV; hepatitis C virus; PEG-IFN; peginterferon alfa; RBV; ribavirin; NS5A protein; Vir